Budget Amount *help |
¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000)
Fiscal Year 2016: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2015: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
Outline of Final Research Achievements |
Induction of exon skipping of the dystrophin gene is the most promising treatment of Duchenne muscular dystrophy. For this 11 out of 79 dystrophin exons are target of exon skipping. It is the best to induce exon skipping by a small chemical. To search for chemical, in vitro splicing system has been established. However, it takes time and cost to analyze splicing product. In this study it was aimed to establish the method to detect exon skipped mRNA. The validity of this splicing system was confirmed, but it is still on the way to establish efficient detection of skipped mRNA.
|